Intuitive Surgical's 30% Stock Drop May Present a Rare Buying Opportunity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Fool
- Market Performance Review: Intuitive Surgical's stock has declined approximately 30% since the beginning of 2026; however, the number of da Vinci surgical systems installed globally has increased by 12% year-over-year, indicating sustained demand and growth potential in the surgical robotics market.
- Surgical Demand Growth: The number of procedures performed using the da Vinci system has risen by 17% year-over-year, demonstrating strong patient demand for robotic surgery, which further solidifies the company's market position and future revenue expectations.
- Diversified Revenue Sources: Intuitive Surgical generates about 25% of its revenue from da Vinci system sales, with the remainder coming from parts and services, creating a stable revenue stream that enhances the business's resilience amid growing demand for surgical robots.
- Investor Confidence Test: Despite the significant stock price drop, Intuitive Surgical's fundamentals remain strong, and historical data shows that the company's stock typically recovers and reaches new highs after similar pullbacks, attracting attention from more aggressive growth investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 402.300
Low
575.00
Averages
637.32
High
740.00
Current: 402.300
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in Healthcare Stocks
- Intuitive Surgical Outlook: Despite a 25% drop in share price this year, Intuitive Surgical's financial performance remains robust, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- HCA Healthcare's Market Position: HCA Healthcare's stock has declined 21% year-to-date, yet its extensive medical network and strong relationships with patients and physicians position it well to benefit from the aging population trend, making it an attractive investment.
- Abbott Laboratories' Innovation: While Abbott Laboratories' nutrition and diagnostics segments have hindered sales growth, its core medical device unit remains strong, particularly in structural heart products and diabetes care, which are expected to drive long-term growth.
- Dividend King's Appeal: Abbott Laboratories has increased its dividends for 54 consecutive years, earning the title of Dividend King, showcasing its stable income potential and long-term investment value, appealing to income-seeking investors.
See More
Investment Opportunities in the Healthcare Sector
- Market Challenges and Opportunities: Despite a challenging macroeconomic environment, Intuitive Surgical's stock has fallen 25% this year; however, its financial performance remains strong, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- Resilience of HCA Healthcare: HCA Healthcare's stock has declined 21% year-to-date due to high cost pressures, yet its extensive medical network across the U.S. and strong relationships with patients and physicians position the company to benefit from long-term trends like an aging population, making it a worthwhile long-term hold.
- Strength of Abbott's Core Business: Although Abbott's nutrition and diagnostics segments have hindered sales growth, its core medical device division remains robust, particularly in structural heart products and diabetes care, which are expected to drive future growth.
- Attractiveness of Dividend King: Abbott has increased its dividends for 54 consecutive years, earning the title of 'Dividend King'; its stable dividend history and innovation capabilities make it a strong investment option for those seeking consistent income over the long term.
See More
Intuitive Surgical's 30% Stock Drop May Present a Rare Buying Opportunity
- Market Performance Review: Intuitive Surgical's stock has declined approximately 30% since the beginning of 2026; however, the number of da Vinci surgical systems installed globally has increased by 12% year-over-year, indicating sustained demand and growth potential in the surgical robotics market.
- Surgical Demand Growth: The number of procedures performed using the da Vinci system has risen by 17% year-over-year, demonstrating strong patient demand for robotic surgery, which further solidifies the company's market position and future revenue expectations.
- Diversified Revenue Sources: Intuitive Surgical generates about 25% of its revenue from da Vinci system sales, with the remainder coming from parts and services, creating a stable revenue stream that enhances the business's resilience amid growing demand for surgical robots.
- Investor Confidence Test: Despite the significant stock price drop, Intuitive Surgical's fundamentals remain strong, and historical data shows that the company's stock typically recovers and reaches new highs after similar pullbacks, attracting attention from more aggressive growth investors.
See More
Intuitive Surgical's da Vinci System Sales Remain Strong Amid Stock Decline
- Sales Growth Trend: As of Q1 2026, the number of installed da Vinci surgical systems reached 11,395 globally, marking a 12% increase year-over-year, indicating that despite stock price declines, product demand remains robust, showcasing the company's sustained competitiveness in the medical device market.
- Surgical Procedure Increase: The number of surgeries performed using the da Vinci system rose by 17% year-over-year, reflecting a growing patient demand for robotic surgery, which lays a solid foundation for future revenue growth and further strengthens the company's market position.
- Revenue Structure Analysis: Although sales of the da Vinci system account for only 25% of the company's revenue, the ongoing demand for parts and services creates a stable revenue stream, and this
See More
Intuitive Surgical Stock Price Correction Analysis
- Market Performance Correction: Intuitive Surgical's stock has fallen over 30% since early 2025; however, Wall Street analysts remain optimistic, with an average price target of $570, indicating a potential rebound of over 30% from current depressed levels.
- Strong Business Model: As a medical device company focused on surgical robots, Intuitive Surgical had 11,395 da Vinci systems installed globally by Q1 2026, reflecting a 12% year-over-year increase, showcasing robust market demand.
- Surgery Demand Growth: The number of surgeries performed by da Vinci robots rose 17% year-over-year, indicating broad demand for robotic surgery, with approximately 75% of revenue derived from instruments and services, creating stable income streams.
- Optimistic Long-Term Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical is poised to benefit from new system sales and increasing patient demand for robotic surgery, with significant market opportunities likely over the next decade.
See More
Intuitive Surgical Stock Nears 52-Week Lows Amid Analyst Optimism
- Stock Decline: Intuitive Surgical's stock has fallen 30% from its recent peak and is trading near 52-week lows; however, analysts remain optimistic, projecting a recovery to $570, representing over a 30% rebound from current depressed levels.
- Surgery Demand Growth: By the end of Q1 2026, the number of installed da Vinci surgical systems reached 11,395, a 12% increase year-over-year, indicating strong demand for robotic surgery that is driving revenue growth for the company.
- Stable Revenue Structure: Approximately 75% of the company's revenue comes from the sale of surgical instruments, accessories, and services, which are annuity-like income streams, suggesting that even a slowdown in new system sales would not derail long-term prospects.
- Broad Market Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical's leadership in medical technology and ongoing market demand indicate significant growth potential over the next decade, making it an attractive option for aggressive growth investors.
See More
Investment Opportunities in Healthcare Stocks
- Intuitive Surgical Outlook: Despite a 25% drop in share price this year, Intuitive Surgical's financial performance remains robust, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- HCA Healthcare's Market Position: HCA Healthcare's stock has declined 21% year-to-date, yet its extensive medical network and strong relationships with patients and physicians position it well to benefit from the aging population trend, making it an attractive investment.
- Abbott Laboratories' Innovation: While Abbott Laboratories' nutrition and diagnostics segments have hindered sales growth, its core medical device unit remains strong, particularly in structural heart products and diabetes care, which are expected to drive long-term growth.
- Dividend King's Appeal: Abbott Laboratories has increased its dividends for 54 consecutive years, earning the title of Dividend King, showcasing its stable income potential and long-term investment value, appealing to income-seeking investors.
See More
Investment Opportunities in the Healthcare Sector
- Market Challenges and Opportunities: Despite a challenging macroeconomic environment, Intuitive Surgical's stock has fallen 25% this year; however, its financial performance remains strong, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- Resilience of HCA Healthcare: HCA Healthcare's stock has declined 21% year-to-date due to high cost pressures, yet its extensive medical network across the U.S. and strong relationships with patients and physicians position the company to benefit from long-term trends like an aging population, making it a worthwhile long-term hold.
- Strength of Abbott's Core Business: Although Abbott's nutrition and diagnostics segments have hindered sales growth, its core medical device division remains robust, particularly in structural heart products and diabetes care, which are expected to drive future growth.
- Attractiveness of Dividend King: Abbott has increased its dividends for 54 consecutive years, earning the title of 'Dividend King'; its stable dividend history and innovation capabilities make it a strong investment option for those seeking consistent income over the long term.
See More
Intuitive Surgical's 30% Stock Drop May Present a Rare Buying Opportunity
- Market Performance Review: Intuitive Surgical's stock has declined approximately 30% since the beginning of 2026; however, the number of da Vinci surgical systems installed globally has increased by 12% year-over-year, indicating sustained demand and growth potential in the surgical robotics market.
- Surgical Demand Growth: The number of procedures performed using the da Vinci system has risen by 17% year-over-year, demonstrating strong patient demand for robotic surgery, which further solidifies the company's market position and future revenue expectations.
- Diversified Revenue Sources: Intuitive Surgical generates about 25% of its revenue from da Vinci system sales, with the remainder coming from parts and services, creating a stable revenue stream that enhances the business's resilience amid growing demand for surgical robots.
- Investor Confidence Test: Despite the significant stock price drop, Intuitive Surgical's fundamentals remain strong, and historical data shows that the company's stock typically recovers and reaches new highs after similar pullbacks, attracting attention from more aggressive growth investors.
See More
Intuitive Surgical's da Vinci System Sales Remain Strong Amid Stock Decline
- Sales Growth Trend: As of Q1 2026, the number of installed da Vinci surgical systems reached 11,395 globally, marking a 12% increase year-over-year, indicating that despite stock price declines, product demand remains robust, showcasing the company's sustained competitiveness in the medical device market.
- Surgical Procedure Increase: The number of surgeries performed using the da Vinci system rose by 17% year-over-year, reflecting a growing patient demand for robotic surgery, which lays a solid foundation for future revenue growth and further strengthens the company's market position.
- Revenue Structure Analysis: Although sales of the da Vinci system account for only 25% of the company's revenue, the ongoing demand for parts and services creates a stable revenue stream, and this
See More
Intuitive Surgical Stock Price Correction Analysis
- Market Performance Correction: Intuitive Surgical's stock has fallen over 30% since early 2025; however, Wall Street analysts remain optimistic, with an average price target of $570, indicating a potential rebound of over 30% from current depressed levels.
- Strong Business Model: As a medical device company focused on surgical robots, Intuitive Surgical had 11,395 da Vinci systems installed globally by Q1 2026, reflecting a 12% year-over-year increase, showcasing robust market demand.
- Surgery Demand Growth: The number of surgeries performed by da Vinci robots rose 17% year-over-year, indicating broad demand for robotic surgery, with approximately 75% of revenue derived from instruments and services, creating stable income streams.
- Optimistic Long-Term Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical is poised to benefit from new system sales and increasing patient demand for robotic surgery, with significant market opportunities likely over the next decade.
See More
Intuitive Surgical Stock Nears 52-Week Lows Amid Analyst Optimism
- Stock Decline: Intuitive Surgical's stock has fallen 30% from its recent peak and is trading near 52-week lows; however, analysts remain optimistic, projecting a recovery to $570, representing over a 30% rebound from current depressed levels.
- Surgery Demand Growth: By the end of Q1 2026, the number of installed da Vinci surgical systems reached 11,395, a 12% increase year-over-year, indicating strong demand for robotic surgery that is driving revenue growth for the company.
- Stable Revenue Structure: Approximately 75% of the company's revenue comes from the sale of surgical instruments, accessories, and services, which are annuity-like income streams, suggesting that even a slowdown in new system sales would not derail long-term prospects.
- Broad Market Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical's leadership in medical technology and ongoing market demand indicate significant growth potential over the next decade, making it an attractive option for aggressive growth investors.
See More
